Appointment of New Director

On June 10, 2020, the board of directors (the “Board”) of Rockwell Medical, Inc. (the “Company”) appointed Allen Nissenson, MD to the Board as a Class I Director to serve until the Company’s 2022 Annual Meeting of Stockholders and until his successor is duly elected and qualified, effective on June 11, 2020.

Dr. Nissenson, age 73, has served as Emeritus Chief Medical Officer of DaVita Kidney Care, a division of DaVita HealthCare Partners, since January 2020. He previously served as Chief Medical Officer of DaVita Kidney Care from August 2008 to December 2019. Dr. Nissenson is also currently an Emeritus Professor of Medicine at the David Geffen School of Medicine at University California Los Angeles, where he previously served as Director of the Dialysis Program and Associate Dean. He has served on the board of Angion Biomedica Corp., a late-stage biopharmaceutical company, since January 2020. He is the immediate past Chair of Kidney Care Partners and immediate past Co-Chair of the Kidney Care Quality Alliance. He is a former president of the Renal Physicians Association and current member of the Government Affairs Committee. Dr. Nissenson also previously served as President of the Southern California End-Stage Renal Disease Network, as well as Chair of the Medical Review Board. Dr. Nissenson earned his B.S. from Northwestern University and his M.D. from Northwestern University Medical School.

In accordance with the Company’s non-employee director compensation policy, which is described in the Company’s Proxy Statement on Schedule 14A (No. 000-23661), Dr. Nissenson will receive an annual cash retainer of $60,000 for his service as a director. In addition, Dr. Nissenson will be granted an option to purchase such number of shares of the Company’s common stock with an aggregate grant date fair value equal to approximately $57,500 using the Company’s current Black-Scholes valuation model at an exercise price equal to the closing price of the Company’s common stock on The Nasdaq Global Market on June 11, 2020 and restricted stock units with an aggregate grant date fair value equal to approximately $57,500 for his service as a director. The aggregate grant date fair value of the equity awards will be calculated using the higher of $2.50 or the closing price of the Company’s common stock on The Nasdaq Global Market on June 11, 2020. The equity awards will be made under the Company’s 2018 Amended and Restated Long Term Incentive Plan. The restricted stock units and the shares underlying the option will vest and become exercisable on June 11, 2021, subject to Dr. Nissenson’s continued service to the Company. Dr. Nissenson will enter into the Company’s standard form of indemnification agreement, which was previously filed by the Company as Exhibit 10.1 to the Company’s Current Report on Form 8-K (No. 000-23661) filed on August 30, 2019.

There are no arrangements or understandings between Dr. Nissenson and any other persons to which he was elected as a director of the Company. There are no family relationships between Dr. Nissenson and any director or executive officer of the Company, and he has no direct or indirect material interest in any transaction required to be disclosed to Item 404(a) of Regulation S-K.

Resignation of Chief Financial Officer

On June 5, 2020, Angus Smith notified the Company of his decision to resign as the Company’s Chief Financial Officer and principal financial officer, effective as of July 3, 2020 (the “Effective Date”), in order to accept another chief financial officer position in the biopharmaceutical industry. Mr. Smith will continue in his current role through the Effective Date and will provide consulting services to the Company for up to three months following the Effective Date to assist with the transition of his responsibilities and other related matters.

About ROCKWELL MEDICAL, INC. (NASDAQ:RMTI)

Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its lead branded drug, Triferic is indicated for iron maintenance. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Its generic drug, Calcitriol, is indicated for treating secondary hyperparathyroidism in dialysis patients. It manufactures, sells, delivers and distributes hemodialysis concentrates, along with a range of ancillary products.